New research in the July 2025 issue of JNCCN-Journal of the National Comprehensive Cancer Network finds that for people diagnosed with nonmetastatic low-risk prostate cancer later in life, and treated ...

Ustekinumab is more efficacious than vedolizumab or anti-TNFs as second- or third-line biologic therapy for perianal Crohn disease.